Respimat, commonly referred to as Respimat SMI (SMI indicates "Soft Mist Inhaler") is an advanced drug delivery device in comparison to MDIs (metered-dose inhalers) or DPIs (dry powder inhalers) used for the treatment of asthma, chronic obstructive pulmonary disease (COPD), and other respiratory conditions.
Its developer, Boehringer Ingelheim, is currently conducting Phase III clinical trials in the U.S. with a variety of their products, such as Spiriva (tiotropium bromide) and Combivent (ipratropium bromde/albuterol).
